

Special Issue

APAA: Asthma Pharmacogenetics across Ages

Message from the Guest Editors

Pharmacogenetics has had substantial impact in the treatment of some diseases, but despite much progress on the genetics of asthma, heterogeneity of asthma across the age spectrum has hindered translation. This Special Issue will focus on age-dependent factors likely to yield important indicators of asthma drug response that are applicable to children and adults. A specific interest is genetic and genomic mechanisms regulating response to asthma treatments including inhaled steroids and beta2-agonists and the differences across the age spectrum. Using age-dependent biomarkers to predict asthma drug response carries tremendous promise to improve asthma management by allowing clinicians to tailor asthma management to individual needs. Emerging results point to less asthma suffering and substantial cost-savings as the number of exacerbations from asthma will decrease. This Special Issue of JPM: APAA will focus on all aspects of pharmacogenetics of asthma; the heterogeneity of asthma subtypes related to age; age-based genetic, metabolomic, transcriptomic, and other broad-based investigations of asthma pharmacology. We welcome all submissions related to these topics.

Guest Editors

Prof. Ann Chen Wu

Center for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215-5301, USA

Dr. Michael McGeachie

Channing Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02215, USA

Deadline for manuscript submissions

closed (5 April 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 7.2
Indexed in PubMed



mdpi.com/si/46887

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 7.2
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).